Clinical Trial Update: Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy [Phase 3]

View source ↗

Summary

The Phase 3 open-label trial evaluating long-term safety and efficacy of seletracetam for epilepsy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Seletracetam (Seletracetam)

Snippet

Sponsor: UCB Pharma | Conditions: Epilepsy | Phase 3 | Status: WITHDRAWN